CEDAR KNOLLS, NJ--(Marketwired - Jan 30, 2017) - According to Dr. Robert Hariri, U.S. Chairman of MYOS RENS Technology Inc. (
"It is becoming increasingly apparent that muscle is a master regulatory tissue which is critical to metabolic and physiologic stability. In fact, building and maintaining lean muscle mass is one of the most important and actionable aspects of preserving overall health and wellness."
"Lean and healthy muscle equals strong bodies, and strong bodies allow us to lead healthier lives even in the face of physical and mental challenges. Whether you want to get more fit, recover faster, or increase your metabolism, muscle is the key to overcoming your body's current limitations."
As Dr. Hariri, both an M.D. and a Ph.D., continued, "It has become clear that myostatin is a key clinical target to address fundamental issues such as sarcopenia, inflammation and aging. MYOS RENS continues to lead in the development of products that target myostatin, and we believe, is the only company that has a safe and effective product on the market to modulate myostatin."
Myostatin, a TGF-β protein, is a negative regulator of muscle growth. In everyday language, that means that myostatin is a compound with negative effects on muscle growth. Therefore, inhibition of myostatin has been investigated as a therapeutic modality by several biotechnology companies for its efficacy in the restoration of muscle lost through diseases and as a normal consequence of aging.
Not only has MYOS RENS Technology been at the forefront of research in this area, it is the first and only company to have actual myostatin-reducing OTC products on the market. Their proprietary product, Fortetropin®, has been clinically proven to reduce serum myostatin levels, leading to increases in muscle size and lean body mass, leading to increases in muscle size and lean body mass. And Fortetropin® is the first safe and all-natural agent clinically shown to improve muscle bulk when used in conjunction with resistance training. These results have been reported in peer-reviewed scientific literature.
No prescription drug can inhibit myostatin
In this vital area of health and wellness, there is no approved prescription drug to rebuild lost muscle by inhibiting myostatin. Fortetropin®, a non-prescription OTC product, stands alone as an effective myostatin-reducing agent.
Joseph Mannello, CEO of MYOS RENS Technology, Inc., noted that "increased attention is being paid to muscle health and the role that muscle and muscular activity plays in regulating or influencing aging, mental acuity, vigor, balance, and other areas throughout a person's life.
Other companies have entered the arena, but MYOS RENS expects to maintain its leadership in researching, formulating, and manufacturing products promoting muscle health and growth.
"I am keenly aware of the growth in interest here. In fact, I read the presentation of Sarepta Therapeutics presented to 9000 investors at the 2017 J.P. Morgan Healthcare Conference in San Francisco. This organization, as well as others, is targeting musculoskeletal diseases, an expanding sphere of scientific focus. This interest validates that we are on course with our ambitious, but realistic, plan for future development, outlined below.
- Launch new products targeting specific applications and demographics
- Clinical evaluation of Fortetropin® in diseases such as sarcopenia (age-related muscle loss) and cachexia (loss of muscle due to diseases).
- Clinical evaluation of effects of Fortetropin® on wellness and aging.
- Evaluation of Fortetropin® and further isolation of active molecules towards the goal of developing more potent products and potential therapeutic applications.
- Aggressively encouraging and investigating partnership opportunities.
About MYOS RENS Technology Inc.
MYOS RENS Technology (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based biotherapeutics and bionutrition company focused on developing products that improve muscle health and performance and bringing them to market. MYOS is the owner of Fortetropin®, the world's first clinically demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Fortetropin® is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYOS and its proprietary ingredient, Fortetropin® visit www.myosrens.com.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of our products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into partnership opportunities, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.